Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00001368 · ClinicalTrials.gov registry record · Phase 1
Potential Risk Factors for Stroke
A Phase 1 study of Hypertension and Diabetes Mellitus, sponsored by National Institute of Neurological Disorders and Stroke (NINDS).
- Completed
- Registry status
- Phase 1
- Development phase
- 500
- Enrollment target
- 1
- Study location
NCT00001368 is a Phase 1 study of Hypertension and Diabetes Mellitus that has completed, run by National Institute of Neurological Disorders and Stroke (NINDS). The registered enrollment target is 500 participants, below the 3,506-participant average among 470 other Hypertension trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00001368, a Phase 1 study of Hypertension and Diabetes Mellitus, has completed, sponsored by National Institute of Neurological Disorders and Stroke (NINDS).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 500 participants
- Enrollment target
- 1
- Study location
Study Summary
Early studies have shown that the immune system may play a role in the development of strokes. Conditions such as high blood pressure, high cholesterol, diabetes, and old age can activate the immune system and increase the risk of developing hardening of the arteries (atherosclerosis) and damaged blood vessels. Researchers will attempt to characterize factors that may contribute to atherosclerosis and stroke by measuring certain components of the immune system, cytokines and leukocyte activation. Measurements will be taken from patients that are considered to be stroke prone and from patients without risk factors for the development of stroke. Researchers will measure the immune system components at the beginning of the study, at six months, and at the one-year completion of the study. The study will attempt to determine; I) If patients with risk factors for stroke have an increased activation of the immune system II) If patients with risk factors for stroke that are symptomatic have higher levels of immune system activation compared to patients who do not have symptoms III) If patients with increased activation of the immune system have accelerated hardening of the arteries (atherosclerosis)
Conditions Studied
Interventions
- PROCEDURE cytokine and leukocyte activation profile
Study Locations (1)
Maryland
- National Institute of Neurological Disorders and Stroke (NINDS) - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 1993-10 |
| Est. Completion | 2002-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00001368
The ClinicalTrials.gov registry entry for NCT00001368 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,506-participant average among 470 other Hypertension trials with a reported enrollment target (86% lower). The listed sponsor is National Institute of Neurological Disorders and Stroke (NINDS), which has 567 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Hypertension appearing as the primary indexed condition, and to 1 intervention - of which cytokine and leukocyte activation profile is the first listed.
NCT00001368 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT00001368 about?
NCT00001368 is a clinical study titled "Potential Risk Factors for Stroke". Early studies have shown that the immune system may play a role in the development of strokes. Conditions such as high blood pressure, high cholesterol, diabetes, and old age can activate the immune system and increase the risk of developing hardening of the arteries (atherosclerosis) and damaged bl...
What is the current status of trial NCT00001368?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 500 participants. The study started on 1993-10. Estimated completion is 2002-11.
What conditions does trial NCT00001368 study?
This clinical trial studies the following conditions: Hypertension, Diabetes Mellitus, Hypercholesterolemia, Cerebrovascular Accident, Carotid Atherosclerosis.
What interventions are being tested in trial NCT00001368?
The interventions under investigation include: cytokine and leukocyte activation profile (PROCEDURE).
Who is sponsoring clinical trial NCT00001368?
This trial is sponsored by National Institute of Neurological Disorders and Stroke (NINDS), which has 567 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00001368 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of LY3971297 in Healthy Participants
RECRUITING · Phase 1
-
Metabolic Effects of Angiotensin-(1-7)
RECRUITING · Phase 1
-
Sympathetic Mechanisms in Obesity-Crossover Design
RECRUITING · Phase 1
-
Targeting Endoplasmic Reticulum Stress in Human Hypertension
RECRUITING · Phase 1
-
: Vascular Function in Health and Disease
RECRUITING · Phase 1
-
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.